Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder. NBI-1070770 is a novel,…
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of DISCOVER TD™, an interactive digital tool designed to help healthcare providers learn about and identify tardive dyskinesia. Built in collaboration with clinical experts and Level Ex, “the world’s leading medical video game studio,” DISCOVER…
